3 results
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…
Since previous findings underline the hypothesis that ER may play a key role as an underlying mechanism leading to (re)victimisation, we suggest that a clinical intervention aimed at enhancing ER skills may decrease (re)victimisation risk. Therefore…
The purpose of the study is to investigate to what extent MMI-0100 is tolerated after multiple administrations.It will also be investigated how quickly and to what extent MMI-0100 is absorbed and eliminated from the body (this is called…